BLVRB / biliverdin reductase B Antibody

BLVRB / biliverdin reductase B Antibody Datasheet

BLVRB / biliverdin reductase B Antibody Product Information

• Immunogen: Recombinant Human BLVRB / biliverdin reductase B protein (Catalog#13151-H07E)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 02
• Ig Type: Mouse IgG2b
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human BLVRB / biliverdin reductase B (rh BLVRB / biliverdin reductase B; Catalog#13151-H07E; P30043; Ala 2-Gln 206). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

BLVRB / biliverdin reductase B Antibody Usage Guide

• Specificity: Human BLVRB / biliverdin reductase B
• No cross-reactivity in ELISA with

  E.coli cell lysate

• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human BLVRB. The detection limit for Human BLVRB is approximately 0.078 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

BLVRB / biliverdin reductase B Antibody Background

Biliverdin reductase (hBVR) is a serine/threonine kinase that catalyzes reduction of the heme oxygenase (HO) activity product, biliverdin, to bilirubin. BVR consists of an N-terminal dinucleotide-binding domain (Rossmann-fold) and a C-terminal domain that contains a six-stranded β-sheet that is flanked on one face by several α-helices. The C-terminal and N-terminal domains interact extensively, forming the active site cleft at their interface. Biliverdin reductase (BVR) catalyzes the last step in heme degradation by reducing the γ-methene bridge of the open tetrapyrrole, biliverdin IXα, to bilirubin with the concomitant oxidation of a β-nicotinamide adenine dinucleotide (NADH) or β-nicotinamide adenine dinucleotide phosphate (NADPH) cofactor. It is now recognized that human BVR (hBVR) is a dual-specificity kinase (Ser/Thr and Tyr) upstream activator of the insulin/insulin growth factor-1 (IGF-1) and mitogen-activated protein kinase (MAPK) signaling pathways. Human BVR (hBVR) is essential for MAPK-extracellular signal-regulated kinase (ERK)1/2 (MEK)-eukaryotic-like protein kinase (Elk) signaling and has been identified as the cytoplasm-nuclear heme transporter of ERK1/2 and hematin, the key components of stress-responsive gene expression.

References

1. Kapitulnik J. et al., 2009, Trends in Pharmacological Sciences. 30 (3): 129-37.
2. Ahmad Z. et al., 2002, Journal of Biological Chemistry. 277: 9226-32.
3. Whitby FG. et al., 2002, Journal of Molecular Biology. 319 (5): 1199-210.